
Verastem (VSTM) Stock Forecast & Price Target
Verastem (VSTM) Analyst Ratings
Bulls say
Verastem is a promising investment opportunity in the biopharmaceutical industry, with a strong pipeline and potential for success in the treatment of various cancers. The company's lead drug candidate, VS-7475, has shown positive results in trials for pancreatic, lung, and colorectal cancers, with manageable side effects. Additionally, Verastem has a partnership model in place for commercialization in the EU which indicates a solid revenue stream in the future. With a focus on developing innovative and effective treatments for cancer patients, Verastem is poised for growth and success in the coming years.
Bears say
Verastem is facing a critical challenge in increasing the efficacy of its main drug, VS-7375, as a potential G12D backbone for multiple tumor types. With recent clinical data showing stronger pharmacologic and dose-dependent activity at the 900 mg QD dose, the company's benchmark in previously treated PDAC is becoming more defined and highly competitive. However, the next step in demonstrating biomarker response and durable disease control, along with maintaining a favorable safety profile, will be crucial for the drug to stand out in the crowded oncology market.
This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares